Bora phosphorylation substitutes in trans for T-loop phosphorylation in Aurora A to promote mitotic entry.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
26 03 2021
Historique:
received: 16 07 2020
accepted: 19 02 2021
entrez: 27 3 2021
pubmed: 28 3 2021
medline: 13 4 2021
Statut: epublish

Résumé

Polo-like kinase 1 (Plk1) is instrumental for mitotic entry and progression. Plk1 is activated by phosphorylation on a conserved residue Thr210 in its activation segment by the Aurora A kinase (AURKA), a reaction that critically requires the co-factor Bora phosphorylated by a CyclinA/B-Cdk1 kinase. Here we show that phospho-Bora is a direct activator of AURKA kinase activity. We localize the key determinants of phospho-Bora function to a 100 amino acid region encompassing two short Tpx2-like motifs and a phosphoSerine-Proline motif at Serine 112, through which Bora binds AURKA. The latter substitutes in trans for the Thr288 phospho-regulatory site of AURKA, which is essential for an active conformation of the kinase domain. We demonstrate the importance of these determinants for Bora function in mitotic entry both in Xenopus egg extracts and in human cells. Our findings unveil the activation mechanism of AURKA that is critical for mitotic entry.

Identifiants

pubmed: 33771996
doi: 10.1038/s41467-021-21922-w
pii: 10.1038/s41467-021-21922-w
pmc: PMC7997955
doi:

Substances chimiques

Cell Cycle Proteins 0
Cyclin A2 0
Proto-Oncogene Proteins 0
bora protein, human 0
Threonine 2ZD004190S
Serine 452VLY9402
Proline 9DLQ4CIU6V
Aurora Kinase A EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1
CDK2 protein, human EC 2.7.11.22
Cyclin-Dependent Kinase 2 EC 2.7.11.22

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1899

Subventions

Organisme : NCI NIH HHS
ID : R33 CA246363
Pays : United States
Organisme : CIHR
ID : MFE 152464
Pays : Canada
Organisme : CIHR
ID : FRN 414829
Pays : Canada
Organisme : CIHR
ID : FDN 143277
Pays : Canada

Références

Cell Cycle. 2016 Dec;15(23):3177-3182
pubmed: 27831827
Mol Cell. 2003 Oct;12(4):851-62
pubmed: 14580337
Nat Commun. 2017 Nov 22;8(1):1701
pubmed: 29167465
Dev Cell. 2006 Aug;11(2):147-57
pubmed: 16890155
EMBO J. 2009 Sep 16;28(18):2786-93
pubmed: 19680222
Proteins. 2005 Jun 1;59(4):687-96
pubmed: 15815974
J Cell Biol. 2015 Mar 16;208(6):661-9
pubmed: 25753036
Cell Mol Life Sci. 2013 Feb;70(4):661-87
pubmed: 22864622
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):13726-13731
pubmed: 27837025
Cell Rep. 2016 Apr 19;15(3):510-518
pubmed: 27068477
Nat Cell Biol. 2003 Feb;5(2):143-8
pubmed: 12524548
Curr Biol. 2003 Apr 15;13(8):691-7
pubmed: 12699628
Cell. 2003 Oct 3;115(1):83-95
pubmed: 14532005
Sci Signal. 2018 Aug 14;11(543):
pubmed: 30108183
Oncogene. 2000 Oct 5;19(42):4906-16
pubmed: 11039908
Cell Cycle. 2004 Apr;3(4):404-7
pubmed: 14752279
Front Oncol. 2015 Jun 10;5:132
pubmed: 26114094
J Cell Sci. 2004 Dec 1;117(Pt 25):5975-83
pubmed: 15536123
Nat Struct Mol Biol. 2013 Sep;20(9):1047-53
pubmed: 23893132
J Biol Chem. 2012 Jan 6;287(2):1150-7
pubmed: 22094468
Dev Cell. 2018 Jun 4;45(5):637-650.e7
pubmed: 29870721
J Cell Biol. 2009 Apr 20;185(2):193-202
pubmed: 19364923
Oncogene. 2004 Nov 18;23(54):8720-30
pubmed: 15480417
Biomolecules. 2019 Jan 15;9(1):
pubmed: 30650622
Nat Commun. 2019 Jul 18;10(1):3166
pubmed: 31320618
Mol Cell. 2004 Sep 10;15(5):799-811
pubmed: 15350223
FEBS J. 2017 Sep;284(18):2947-2954
pubmed: 28342286
Elife. 2018 Feb 21;7:
pubmed: 29465396
J Biomol NMR. 1995 Nov;6(3):277-93
pubmed: 8520220
J Biol Chem. 2001 Dec 7;276(49):46219-24
pubmed: 11551964
Nat Rev Mol Cell Biol. 2014 Jul;15(7):433-52
pubmed: 24954208
J Cell Biol. 2010 Dec 27;191(7):1315-32
pubmed: 21187329
Open Biol. 2018 Aug;8(8):
pubmed: 30135239
Nat Cell Biol. 2003 Mar;5(3):242-8
pubmed: 12577065
Elife. 2014 May 27;3:e02667
pubmed: 24867643
Science. 2008 Jun 20;320(5883):1655-8
pubmed: 18566290
J Biol Chem. 2004 Mar 5;279(10):9008-15
pubmed: 14701852
Nature. 2008 Sep 4;455(7209):119-23
pubmed: 18615013
J Biol Chem. 2002 Nov 15;277(46):44115-20
pubmed: 12207013
Oncogene. 2015 Sep 10;34(37):4799-807
pubmed: 25619835
Oncogene. 2006 Nov 16;25(54):7148-58
pubmed: 16715125
Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12564-9
pubmed: 20538976
Cell Mol Life Sci. 2010 Jun;67(12):1957-70
pubmed: 20148280
J Cell Sci. 1998 Jun;111 ( Pt 12):1751-7
pubmed: 9601104
Cancers (Basel). 2020 Apr 06;12(4):
pubmed: 32268485
Nat Chem Biol. 2017 Apr;13(4):402-408
pubmed: 28166210
J Biol Chem. 2014 Jun 20;289(25):17480-96
pubmed: 24825897
Carcinogenesis. 2016 Dec;37(12):1180-1189
pubmed: 27624071
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15440-5
pubmed: 12422018
J Cell Sci. 2007 Sep 1;120(Pt 17):2987-96
pubmed: 17715155
EMBO J. 2003 Nov 3;22(21):5757-68
pubmed: 14592974
Oncotarget. 2017 Jul 4;8(27):43838-43852
pubmed: 28402276
J Cell Sci. 2014 Feb 15;127(Pt 4):801-11
pubmed: 24338364
Plant Methods. 2012 Jun 28;8(1):23
pubmed: 22741569
Trends Cell Biol. 2017 Jan;27(1):26-41
pubmed: 27528558
Oncogene. 2017 Aug 24;36(34):4819-4827
pubmed: 28436952
J Cell Sci. 2010 Jul 1;123(Pt 13):2281-91
pubmed: 20554897
Cell Rep. 2016 Apr 5;15(1):210-218
pubmed: 27052166
ACS Chem Biol. 2017 Nov 17;12(11):2906-2914
pubmed: 29045126
Curr Biol. 2005 Dec 6;15(23):2156-63
pubmed: 16332542
Chromosoma. 2008 Oct;117(5):457-69
pubmed: 18521620
EMBO J. 2018 Apr 13;37(8):
pubmed: 29510984
Life Sci Alliance. 2021 Jan 5;4(3):
pubmed: 33402344
Science. 2003 Feb 21;299(5610):1228-31
pubmed: 12595692
J Cell Biol. 2002 Aug 19;158(4):617-23
pubmed: 12177045
J Cell Sci. 1996 Jan;109 ( Pt 1):239-46
pubmed: 8834808
J Biol Chem. 1997 Apr 25;272(17):11057-62
pubmed: 9110999
Nat Methods. 2009 May;6(5):343-5
pubmed: 19363495
Cell Cycle. 2015 Aug 3;14(15):2394-8
pubmed: 26038951
BMB Rep. 2014 May;47(5):249-55
pubmed: 24667170
Nat Rev Mol Cell Biol. 2009 Apr;10(4):265-75
pubmed: 19305416
Nat Rev Mol Cell Biol. 2001 Jan;2(1):21-32
pubmed: 11413462
Cell Rep. 2017 Jun 6;19(10):2060-2073
pubmed: 28591578
Biochem J. 2018 Jun 26;475(12):2025-2042
pubmed: 29946042

Auteurs

N Tavernier (N)

Centre for Systems Biology, Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.
Programme équipe Labellisée Ligue Contre le Cancer, Institut Jacques Monod, UMR7592, Université de Paris, CNRS, Paris, France.

Y Thomas (Y)

Programme équipe Labellisée Ligue Contre le Cancer, Institut Jacques Monod, UMR7592, Université de Paris, CNRS, Paris, France.

S Vigneron (S)

Centre de Recherche de Biologie cellulaire de Montpellier, UMR 5237, Université de Montpellier, CNRS, Montpellier, France.

P Maisonneuve (P)

Centre for Systems Biology, Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.

S Orlicky (S)

Centre for Systems Biology, Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.

P Mader (P)

Centre for Systems Biology, Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.

S G Regmi (SG)

Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA.

L Van Hove (L)

Programme équipe Labellisée Ligue Contre le Cancer, Institut Jacques Monod, UMR7592, Université de Paris, CNRS, Paris, France.

N M Levinson (NM)

Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA.

G Gasmi-Seabrook (G)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

N Joly (N)

Programme équipe Labellisée Ligue Contre le Cancer, Institut Jacques Monod, UMR7592, Université de Paris, CNRS, Paris, France.

M Poteau (M)

Institut Gustave Roussy CNRS UMR9019, Villejuif, France.

G Velez-Aguilera (G)

Programme équipe Labellisée Ligue Contre le Cancer, Institut Jacques Monod, UMR7592, Université de Paris, CNRS, Paris, France.

O Gavet (O)

Institut Gustave Roussy CNRS UMR9019, Villejuif, France.

A Castro (A)

Centre de Recherche de Biologie cellulaire de Montpellier, UMR 5237, Université de Montpellier, CNRS, Montpellier, France.

M Dasso (M)

Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA.

T Lorca (T)

Centre de Recherche de Biologie cellulaire de Montpellier, UMR 5237, Université de Montpellier, CNRS, Montpellier, France.

F Sicheri (F)

Centre for Systems Biology, Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada. sicheri@lunenfeld.ca.
Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada. sicheri@lunenfeld.ca.
Department of Biochemistry, University of Toronto, Toronto, ON, Canada. sicheri@lunenfeld.ca.

L Pintard (L)

Programme équipe Labellisée Ligue Contre le Cancer, Institut Jacques Monod, UMR7592, Université de Paris, CNRS, Paris, France. Lionel.pintard@ijm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH